{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:36:12Z","timestamp":1781775372971,"version":"3.54.5"},"reference-count":324,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Messenger RNA (mRNA) vaccines against COVID\u201019 are the first authorized biological preparations developed using this platform. During the pandemic, their administration has been proven to be a life\u2010saving intervention. Here, we review the main advantages of using mRNA vaccines, identify further technological challenges to be met during the development of the mRNA platform, and provide an update on the clinical progress on leading mRNA vaccine candidates against different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah virus, Zika virus, human cytomegalovirus, and Epstein\u2010Barr virus. The prospects and challenges of manufacturing mRNA vaccines in low\u2010income countries are also discussed. The ongoing interest and research in mRNA technology are likely to overcome some existing challenges for this technology (e.g., related to storage conditions and immunogenicity of some components of lipid nanoparticles) and enhance the portfolio of vaccines against diseases for which classical formulations are already authorized. It may also open novel pathways of protection against infections and their consequences for which no safe and efficient immunization methods are currently available.<\/jats:p>","DOI":"10.1002\/jmv.28572","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T10:11:27Z","timestamp":1676023887000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["mRNA vaccines: The future of prevention of viral infections?"],"prefix":"10.1002","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4713-0801","authenticated-orcid":false,"given":"Piotr","family":"Rzymski","sequence":"first","affiliation":[{"name":"Department of Environmental Medicine Poznan University of Medical Sciences Pozna\u0144 Poland"},{"name":"Integrated Science Association (ISA) Universal Scientific Education and Research Network (USERN) Pozna\u0144 Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szuster\u2010Ciesielska","sequence":"additional","affiliation":[{"name":"Department of Virology and Immunology, Institute of Biological Sciences Maria Curie\u2010Sk\u0142odowska University Lublin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Dzieci\u0105tkowski","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Medical University of Warsaw Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willis","family":"Gwenzi","sequence":"additional","affiliation":[{"name":"Alexander von Humboldt Fellow &amp; Guest Professor, Grassland Science and Renewable Plant Resources, Faculty of Organic Agricultural Sciences Universit\u00e4t Kassel Witzenhausen Germany"},{"name":"Alexander von Humboldt Fellow &amp; Guest Professor Leibniz Institute for Agricultural Engineering and Bioeconomy (ATB) Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Fal","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Warsaw Faculty of Medicine Cardinal Stefan Wyszynski University Warsaw Poland"},{"name":"Department of Public Health Wroc\u0142aw Medical University Wroc\u0142aw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/190581a0"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/190576a0"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/274923a0"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(76)90136-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230749"},{"issue":"7","key":"e_1_2_11_7_1","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry RM","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636617"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq347"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr586"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114416"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.589959"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1261\/rna.701307"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa032"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.12.011"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070734"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.37140"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaa274"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951215"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050754"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017"},{"issue":"100134","key":"e_1_2_11_27_1","article-title":"Real\u2010world effectiveness of the mRNA\u20101273 vaccine against COVID\u201019: interim results from a prospective observational cohort study","volume":"6","author":"Bruxvoort KJ","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.770"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27487"},{"key":"e_1_2_11_30_1","article-title":"COVID\u201019 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS\u2010CoV\u20102 Omicron wave in the first quarter of 2022","volume":"95","author":"Rzymski P","year":"2022","journal-title":"J Med Virol"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10030437"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr2111445"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03686-x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15010149"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.16403","article-title":"Differences between the course of SARS\u2010CoV\u20102 infections in the periods of the Delta and Omicron variants dominance in Poland","author":"Dobrowolska K","year":"2023","journal-title":"Pol Arch Med Wewn"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100556"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061752"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040382"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111286"},{"key":"e_1_2_11_41_1","unstructured":"Moderna. Moderna's Work on a Potential Vaccine Against COVID\u201019. Published 2020. Accessed October 262022.https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312520074867\/d884510dex991.htm"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00950-y"},{"key":"e_1_2_11_43_1","unstructured":"FDA.Coronavirus (COVID\u201019) update: FDA recommends inclusion of omicron BA.4\/5 component for COVID\u201019 vaccine booster doses.U.S. Food and Drug Administration. Published 2022. Accessed Oct ober 272022.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster"},{"key":"e_1_2_11_44_1","unstructured":"FDACoronavirus (COVID\u201019) update: FDA authorizes Moderna Pfizer\u2010BioNTech bivalent COVID\u201019 vaccines for use as a booster dose. U.S. Food and Drug Administration. Published 2022. Accessed October 272022.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.031"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.08.052"},{"key":"e_1_2_11_48_1","doi-asserted-by":"crossref","unstructured":"JacksonLA AndersonEJ RouphaelNG et al. An mRNA Vaccine against SARS\u2010CoV\u20102 \u2014 Preliminary Report. Published online2020.doi:10.1056\/NEJMoa2022483","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-022-00525-3"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.820544"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2020.10.001"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.1c00080"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix489"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1086\/374604"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03841-4"},{"key":"e_1_2_11_57_1","article-title":"CD8 T cells contribute to vaccine protection against SARS\u2010CoV\u20102 in macaques","volume":"9","author":"Liu J","year":"2022","journal-title":"Sci Immunol. Published online August"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100355"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04465-y"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19537-2"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32324-x"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149335"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081189"},{"key":"e_1_2_11_65_1","unstructured":"WHO. Annex 2 Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses (Addendum 2003 to the Recommendations for the Production and Quality Control of Poliomyelitis Vaccine (Inactivated)). Published 2003. Accessed October 282022.https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/vaccine-quality\/guidelines-for-the-safe-production-and-quality-control-of-inactivated-poliomyelitis-vaccine-manufactured-from-wild-polioviruses7e2f4b76-e117-46ae-ba75-4d6e4828a94c.pdf?sfvrsn=59eaf5a2_1%26download=true"},{"key":"e_1_2_11_66_1","unstructured":"WHO. Guidelines to assure the quality safety and efficacy of live attenuated rotavirus vaccines (oral) Annex 3 TRS No 941. Published 2007. Accessed October 282022.https:\/\/www.who.int\/publications\/m\/item\/oral-live-attenuated-rotavirus-vaccines-annex-3-trs-no-941"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2014.00116"},{"key":"e_1_2_11_68_1","unstructured":"MecklinJThreatened pandemics and laboratory escapes: Self\u2010fulfilling prophecies.Bulletin of the Atomic Scientists. Published March 31 2014. Accesse d October 282022.https:\/\/thebulletin.org\/2014\/03\/threatened-pandemics-and-laboratory-escapes-self-fulfilling-prophecies\/"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003729"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.03.032"},{"key":"e_1_2_11_72_1","unstructured":"ACIP. ACIP contraindications guidelines for Immunization. Published 2022. Ac cessed October 282022.https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/contraindications.html"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000109392.96411.4f"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001783"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003161"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.704773"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16766"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225829"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261350"},{"key":"e_1_2_11_80_1","unstructured":"FDA. Coronavirus (COVID\u201019) update: FDA authorizes Moderna and Pfizer\u2010BioNTech COVID\u201019 vaccines for children down to 6 months of age. U.S. Food and Drug Administration. Published 2022. Accessed O ctober 282022.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children"},{"key":"e_1_2_11_81_1","unstructured":"EMA.EMA recommends approval of Comirnaty and Spikevax COVID\u201019 vaccines for children from 6 months of age.European Medicines Agency. Published October19 2022. Accessed October 282022.https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-comirnaty-spikevax-covid-19-vaccines-children-6-months-age"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209367"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7135a3"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1459394"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1604231"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.033"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0350-4"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01168-4"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801238-3.00079-9"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-08"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2039"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00909"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.05.012"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01160-y"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.04.011"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269727"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108906"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00054-8"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-022-00411-5"},{"key":"e_1_2_11_101_1","unstructured":"Euorpean Medicine Agency. Comirnaty. Summary Of Product Characteristics. Published 2022. Accesse d October 272022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf"},{"key":"e_1_2_11_102_1","unstructured":"European Medicine Agency. Spikevax. Summary Of Product Characteristics. Published 2021. Accessed October 272022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9091033"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.12.006"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.789427"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00677-0"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.024"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006108"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200902672"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.03.073"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.066"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1967"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.023"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.11.042"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c04543"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1339"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103841"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-39981-4.00015-4"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10040504"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228463"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13818"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.5603\/MRJ.a2022.0043"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.07.021"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030595"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.02.043"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.02.012"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00170"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.05.048"},{"key":"e_1_2_11_129_1","first-page":"1","article-title":"Myocarditis after COVID\u201019 mRNA vaccination: clinical observations and potential mechanisms","volume":"9","author":"Heymans S","year":"2021","journal-title":"Nat Rev Cardiol. Published online December"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2022.09.002"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108480"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2021.08.012"},{"key":"e_1_2_11_133_1","unstructured":"FDA. Vaccines and related biological products advisory committee meeting June 7 2022 FDA briefing document novavax COVID\u201019 vaccine. Published 2022. Accessed Novem ber 52022.https:\/\/www.fda.gov\/media\/158912\/download"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.937"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab707"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-022-00361-4"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1646576"},{"key":"e_1_2_11_138_1","doi-asserted-by":"crossref","unstructured":"KajanJ Sabli\u0107M HefferMAspiration during vaccination: Evidence for SARS\u2010CoV\u20102 vaccination 1. Published 2022. Accessed November 52022.https:\/\/hrcak.srce.hr\/file\/399475","DOI":"10.26332\/seemedj.v6i1.237"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab741"},{"issue":"1161","key":"e_1_2_11_140_1","first-page":"2021","article-title":"Inadvertent injection of COVID\u201019 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions","volume":"98","author":"Merchant H","year":"2021","journal-title":"Postgrad Med J"},{"key":"e_1_2_11_141_1","unstructured":"Sanofi.Sanofi announces positive Phase 1\/2 study interim results for its first mRNA\u2010based vaccine candidate.Sanofi. Published 2021. Accessed 2 December2022.https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-09-28-06-00-00-2304069"},{"key":"e_1_2_11_142_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.9.4171"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R110.117531"},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.683152"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1353\/bhm.2002.0022"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02590-14"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31201-0"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00150-11"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70121-4"},{"key":"e_1_2_11_150_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01615"},{"key":"e_1_2_11_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33293-2"},{"key":"e_1_2_11_152_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.020421"},{"issue":"1","key":"e_1_2_11_153_1","first-page":"41","article-title":"Available influenza vaccines: immunization strategies, history and new tools for fighting the disease","volume":"57","author":"Barberis I","year":"2016","journal-title":"J Prev Med Hyg"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4595"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2016-0012"},{"key":"e_1_2_11_156_1","first-page":"181","article-title":"Live attenuated influenza vaccine","volume":"386","author":"Jin H","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab395"},{"key":"e_1_2_11_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00176-7"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.074"},{"key":"e_1_2_11_160_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0271"},{"key":"e_1_2_11_161_1","unstructured":"WHO. HIV. Published 2022. Accessed 5 November2022.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids"},{"key":"e_1_2_11_162_1","unstructured":"UNAIDS. 90\u201390\u201390 \u2010 An ambitious treatment target to help end the AIDS epidemic. Published 2014. Accessed 5 November2022.https:\/\/www.unaids.org\/en\/resources\/documents\/2017\/90-90-90"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272405"},{"key":"e_1_2_11_164_1","unstructured":"UNAIDS. Fast\u2010track \u2010 ending the AIDS epidemic by 2030. Published 2014. Accessed November 52022.https:\/\/www.unaids.org\/en\/resources\/documents\/2014\/JC2686_WAD2014report"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002983"},{"key":"e_1_2_11_166_1","unstructured":"HIV Resource Tracking Working Group. HIV Resource Tracking working group. HIV Resource Tracking Working Group. Published 2021 Accessed 5 November2022.https:\/\/www.hivresourcetracking.org\/"},{"key":"e_1_2_11_167_1","unstructured":"National Institute of Allergy and Infectious Diseases. History of HIV vaccine research. Published 2021. Accessed 5 November2022.https:\/\/www.niaid.nih.gov\/diseases-conditions\/hiv-vaccine-research-history"},{"key":"e_1_2_11_168_1","unstructured":"Experimental HIV vaccine regimen safe but ineffective study finds. National Institutes of Health (NIH). Published January 18 2023. Accessed 1 February2023.https:\/\/www.nih.gov\/news-events\/news-releases\/experimental-hiv-vaccine-regimen-safe-ineffective-study-finds"},{"key":"e_1_2_11_169_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590780"},{"key":"e_1_2_11_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61054-X"},{"key":"e_1_2_11_171_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00198-11"},{"key":"e_1_2_11_172_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000106"},{"key":"e_1_2_11_173_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad9195"},{"key":"e_1_2_11_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.07.005"},{"key":"e_1_2_11_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00042-2"},{"key":"e_1_2_11_176_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.add6502"},{"key":"e_1_2_11_177_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630"},{"key":"e_1_2_11_178_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02905-14"},{"key":"e_1_2_11_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.08.016"},{"key":"e_1_2_11_180_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-16"},{"key":"e_1_2_11_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0"},{"key":"e_1_2_11_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30938-8"},{"key":"e_1_2_11_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60206-1"},{"key":"e_1_2_11_184_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz059"},{"key":"e_1_2_11_185_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1958610"},{"key":"e_1_2_11_186_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit839"},{"key":"e_1_2_11_187_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12912"},{"key":"e_1_2_11_188_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120955"},{"key":"e_1_2_11_189_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120954"},{"key":"e_1_2_11_190_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep34108"},{"key":"e_1_2_11_191_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02180-16"},{"key":"e_1_2_11_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.014"},{"key":"e_1_2_11_193_1","doi-asserted-by":"publisher","DOI":"10.1086\/427813"},{"key":"e_1_2_11_194_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.25.13961"},{"key":"e_1_2_11_195_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.37.1.397-400.1982"},{"key":"e_1_2_11_196_1","doi-asserted-by":"publisher","DOI":"10.1086\/315859"},{"key":"e_1_2_11_197_1","first-page":"259","article-title":"Live\u2010attenuated respiratory syncytial virus vaccines","volume":"372","author":"Karron RA","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_2_11_198_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1829899"},{"key":"e_1_2_11_199_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0163-z"},{"key":"e_1_2_11_200_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2022.10.001"},{"key":"e_1_2_11_201_1","unstructured":"Moderna. Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) vaccine (mRNA\u20101345). Published 2021. Accessed 3 December2022.https:\/\/investors.modernatx.com\/news\/news-details\/2021\/Moderna-Receives-FDA-Fast-Track-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-mRNA-1345\/default.aspx"},{"key":"e_1_2_11_202_1","unstructured":"Moderna. Moderna announces mRNA\u20101345 an investigational respiratory syncytial virus (RSV) vaccine has met primary efficacy endpoints in phase 3 trial in older adults. Published 2023. Accessed 1 February2023.https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults\/default.aspx"},{"key":"e_1_2_11_203_1","unstructured":"Moderna. Moderna granted FDA Breakthrough Therapy Designation for mRNA\u20101345 an investigational respiratory syncytial virus (RSV) vaccine candidate. Published 2023. Accessed 1 February2023.https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Granted-FDA-Breakthrough-Therapy-Designation-for-mRNA-1345-An-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Candidate\/default.aspx"},{"key":"e_1_2_11_204_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00186-z"},{"key":"e_1_2_11_205_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106062"},{"key":"e_1_2_11_206_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32188-1"},{"key":"e_1_2_11_207_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071083"},{"key":"e_1_2_11_208_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819000086"},{"key":"e_1_2_11_209_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1612.091790"},{"key":"e_1_2_11_210_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2010"},{"key":"e_1_2_11_211_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21178"},{"key":"e_1_2_11_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2008.08.007"},{"key":"e_1_2_11_213_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.05.009"},{"key":"e_1_2_11_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2013.01.005"},{"key":"e_1_2_11_215_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1212.060732"},{"key":"e_1_2_11_216_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.07.011"},{"key":"e_1_2_11_217_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1307.061128"},{"key":"e_1_2_11_218_1","unstructured":"WHO. R&D blue print and Ebola\/Marburg. Published 2016. A ccessed December 22022.https:\/\/www.who.int\/teams\/blueprint\/nipah"},{"key":"e_1_2_11_219_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-237"},{"key":"e_1_2_11_220_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004241"},{"key":"e_1_2_11_221_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz553"},{"key":"e_1_2_11_222_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772864"},{"key":"e_1_2_11_223_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2207.151990"},{"key":"e_1_2_11_224_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjtm.2016.06.019"},{"key":"e_1_2_11_225_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40709-020-00115-4"},{"key":"e_1_2_11_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjtm.2017.03.020"},{"key":"e_1_2_11_227_1","doi-asserted-by":"publisher","DOI":"10.1111\/gcb.15384"},{"key":"e_1_2_11_228_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2301.161394"},{"key":"e_1_2_11_229_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000414"},{"key":"e_1_2_11_230_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30432-1"},{"key":"e_1_2_11_231_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.17.201541"},{"key":"e_1_2_11_232_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1604338"},{"key":"e_1_2_11_233_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a1"},{"key":"e_1_2_11_234_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111816"},{"key":"e_1_2_11_235_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3297"},{"key":"e_1_2_11_236_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06482-0"},{"key":"e_1_2_11_237_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060"},{"key":"e_1_2_11_238_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001760"},{"key":"e_1_2_11_239_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.017"},{"key":"e_1_2_11_240_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21428"},{"key":"e_1_2_11_241_1","article-title":"An optimized messenger RNA vaccine candidate protects non\u2010human primates from Zika virus infection","author":"Bollman B","year":"2022","journal-title":"bioRxiv"},{"key":"e_1_2_11_242_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12002"},{"key":"e_1_2_11_243_1","doi-asserted-by":"publisher","DOI":"10.36233\/0507-4088-2020-65-4-191-202"},{"key":"e_1_2_11_244_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511545313.004"},{"key":"e_1_2_11_245_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.10.010405"},{"key":"e_1_2_11_246_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2010.02.017"},{"key":"e_1_2_11_247_1","doi-asserted-by":"publisher","DOI":"10.3390\/v1030737"},{"key":"e_1_2_11_248_1","doi-asserted-by":"publisher","DOI":"10.1136\/mp.52.6.307"},{"key":"e_1_2_11_249_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734293"},{"key":"e_1_2_11_250_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-9-38"},{"key":"e_1_2_11_251_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03824-y"},{"key":"e_1_2_11_252_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"e_1_2_11_253_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.642384"},{"key":"e_1_2_11_254_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7"},{"key":"e_1_2_11_255_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734471"},{"key":"e_1_2_11_256_1","first-page":"1","article-title":"Epstein\u2010Barr virus and multiple sclerosis","volume":"5","author":"Soldan SS","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"e_1_2_11_257_1","article-title":"Finding a vaccine for Epstein\u2010Barr virus","author":"O'Leary K","year":"2022","journal-title":"Nature Med"},{"key":"e_1_2_11_258_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/56.4.697"},{"key":"e_1_2_11_259_1","doi-asserted-by":"publisher","DOI":"10.1086\/523813"},{"key":"e_1_2_11_260_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890130310"},{"key":"e_1_2_11_261_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890290114"},{"key":"e_1_2_11_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.021"},{"key":"e_1_2_11_263_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.010"},{"key":"e_1_2_11_264_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005549"},{"key":"e_1_2_11_265_1","unstructured":"NIH launches clinical trial of Epstein\u2010Barr virus vaccine. Published May 6 2022. Acce ssed November 92022. National Institutes of Health (NIH).https:\/\/www.nih.gov\/news-events\/news-releases\/nih-launches-clinical-trial-epstein-barr-virus-vaccine"},{"key":"e_1_2_11_266_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05598-11"},{"key":"e_1_2_11_267_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020169"},{"key":"e_1_2_11_268_1","unstructured":"Moderna. Moderna announces first participant dosed in phase 1 study of its mRNA Epstein\u2010Barr virus (EBV) vaccine. Published 2022. Accessed N ovember 92022.https:\/\/investors.modernatx.com\/news\/news-details\/2022\/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-its-mRNA-Epstein-Barr-Virus-EBV-Vaccine\/default.aspx"},{"key":"e_1_2_11_269_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12534"},{"key":"e_1_2_11_270_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509201102"},{"key":"e_1_2_11_271_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01336-18"},{"key":"e_1_2_11_272_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.655"},{"key":"e_1_2_11_273_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.535"},{"key":"e_1_2_11_274_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.12.010"},{"key":"e_1_2_11_275_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00455-09"},{"key":"e_1_2_11_276_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2017.12.010"},{"key":"e_1_2_11_277_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z"},{"key":"e_1_2_11_278_1","doi-asserted-by":"publisher","DOI":"10.1002\/pd.4118"},{"key":"e_1_2_11_279_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0172-6"},{"key":"e_1_2_11_280_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41372-019-0501-z"},{"key":"e_1_2_11_281_1","unstructured":"AkpanUS PillarisettyLSCongenital Cytomegalovirus Infection. Published online January 2022. Accessed November 92022.https:\/\/pubmed.ncbi.nlm.nih.gov\/31082047\/"},{"key":"e_1_2_11_282_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001140"},{"key":"e_1_2_11_283_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20736"},{"key":"e_1_2_11_284_1","unstructured":"Cytomegalovirus CMV) and congenital CMV infection. Published March 18 2021 Accessed November 92022.https:\/\/www.cdc.gov\/cmv\/index.html"},{"key":"e_1_2_11_285_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14020352"},{"key":"e_1_2_11_286_1","volume-title":"Vaccines for the 21st Century","author":"Stratton KR","year":"2001"},{"key":"e_1_2_11_287_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2005.09.019"},{"key":"e_1_2_11_288_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1242"},{"key":"e_1_2_11_289_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804749"},{"key":"e_1_2_11_290_1","unstructured":"Moderna. Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA\u20101647) Study and Progress Toward Phase 2 and Pivotal Trials. Published 2019. Accessed 9 November2022.https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312519243385\/d796420dex991.htm"},{"key":"e_1_2_11_291_1","unstructured":"Moderna. Moderna's latent & public health vaccines: CMV vaccine (mRNA\u20101647). Published 2022. Accessed 11 September2022.https:\/\/s29.q4cdn.com\/435878511\/files\/doc_downloads\/program_detail\/2022\/CMV-(05-04-22).pdf"},{"key":"e_1_2_11_292_1","doi-asserted-by":"publisher","DOI":"10.1086\/340637"},{"key":"e_1_2_11_293_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01294-2"},{"key":"e_1_2_11_294_1","unstructured":"United Nations. World Population Prospects 2022: Summary of results. Published 2022. Accessed 25 November2022.https:\/\/www.un.org\/development\/desa\/pd\/content\/World-Population-Prospects-2022"},{"key":"e_1_2_11_295_1","unstructured":"United Nations. WHO reveals countries to produce first COVID\u2010busting mRNA vaccines in Africa. UN News. Published February 18 2022. Accessed 25 November2022.https:\/\/news.un.org\/en\/story\/2022\/02\/1112212"},{"key":"e_1_2_11_296_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00328-2"},{"key":"e_1_2_11_297_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.06.017"},{"key":"e_1_2_11_298_1","unstructured":"World Health Organization. Covax announces new agreement plans for first deliveries. Published February 2021. Accessed November 25 2022.https:\/\/www.who.int\/news\/item\/22-01-2021-covax-announces-new-agreement-plans-for-first-deliveries"},{"key":"e_1_2_11_299_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00129-6"},{"key":"e_1_2_11_300_1","unstructured":"Treaty for the establishment of the African Medicines Agency. Africa Union. Published 2022. Accessed 25 November2022.https:\/\/au.int\/sites\/default\/files\/treaties\/36892-treaty-0069_-_ama_treaty_e.pdf"},{"key":"e_1_2_11_301_1","article-title":"First African\u2010made mRNA vaccine, a test platform for the future","author":"Dutton J","year":"2022","journal-title":"Nature Africa"},{"key":"e_1_2_11_302_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01268-4"},{"key":"e_1_2_11_303_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216287"},{"key":"e_1_2_11_304_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106833"},{"key":"e_1_2_11_305_1","volume-title":"Brookings","author":"Holtz L","year":"2022"},{"key":"e_1_2_11_306_1","unstructured":"India Brand Equity Foundation. Pharmaceutical companies in India Indian pharma industry\u2010 IBEF. India Brand Equity Foundation. Published 2022. Accessed 25 November2022.https:\/\/www.ibef.org\/industry\/pharmaceutical-india"},{"key":"e_1_2_11_307_1","unstructured":"IAVI and Moderna launch first\u2010in\u2010Africa clinical trial of mRNA HIV vaccine development program. IAVI. Published 2021. Accessed 25 November2022.https:\/\/www.iavi.org\/news-resources\/press-releases\/2022\/iavi-and-moderna-launch-first-in-africa-clinical-trial-of-mrna-hiv-vaccine-development-program"},{"key":"e_1_2_11_308_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00243-1"},{"key":"e_1_2_11_309_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2008.08.001"},{"key":"e_1_2_11_310_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.06.007"},{"key":"e_1_2_11_311_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-02774-8"},{"key":"e_1_2_11_312_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.03.038"},{"key":"e_1_2_11_313_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.718753"},{"key":"e_1_2_11_314_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13503"},{"key":"e_1_2_11_315_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2020.110637"},{"key":"e_1_2_11_316_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.22.287958"},{"key":"e_1_2_11_317_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00457"},{"key":"e_1_2_11_318_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1448-9"},{"key":"e_1_2_11_319_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2017.11.121"},{"key":"e_1_2_11_320_1","unstructured":"GennariA HoltT JordiE KaplowLAfrica needs vaccines. What would it take to make them here?Published April 14 2021. Accessed 25 November2022.https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/africa-needs-vaccines-what-would-it-take-to-make-them-here"},{"key":"e_1_2_11_321_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.technovation.2021.102268"},{"key":"e_1_2_11_322_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.054"},{"key":"e_1_2_11_323_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9040301"},{"key":"e_1_2_11_324_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdrr.2022.103350"},{"key":"e_1_2_11_325_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14020401"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.28572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.28572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.28572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T12:34:54Z","timestamp":1722602094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.28572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":324,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/jmv.28572"],"URL":"https:\/\/doi.org\/10.1002\/jmv.28572","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2023-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e28572"}}